First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Summary

This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or refractory AML.

Timeline

Start

2015-04-08

Primary completion

2017-05-03

Completion

2017-05-03

Outcome

Outcome not reported

Stopped (Business): “Dose escalation completed; Sponsor decision”

Drugs

Indications